CoChat

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

Characterization of KRASG12C inhibitor olomorasib single-agent and combination with activity in KRASG12C-mutant models

Open access

Abstract

The impact of first-generation covalent KRAS G12C inhibitors has been reduced due to the development of drug resistance, tolerability and challenges combining with immunotherapy. We designed olomorasib, a next-generation GDP-binding KRAS G12C inhibitor, for nanomolar potency as well as selectivity over wild-type inhibition. In both in vitro and in vivo models of KRAS G12C -mutant cancers, olomorasib reduces RAS activity and pERK levels, leading to substantial and significant tumor growth inhibition. Additionally, olomorasib combined with immune checkpoint inhibitors demonstrates greater anti-tumor activity compared to monotherapy. Furthermore, we demonstrate that olomorasib binds tightly to KRAS G12C even in the presence of clinically relevant second site mutations, a known mechanism of resistance and limitation to currently approved KRAS G12C inhibitors. These findings suggest that olomorasib could be effective for patients with KRAS G12C mutant cancers either as monotherapy or in combination with immunotherapy. Olomorasib monotherapy and combination treatments are currently being investigated clinically.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-026-72650-y

Cites

0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

The publisher hasn’t deposited this paper’s reference list.

Cited by

See all 2

Metadata

Authors
Peng, S., Zhang, Y., Lin, X., Si, C., Van Horn, R. D., Dempsey, J. A., Goetz, E., Evans, R. J., Farber, A., Vandekopple, M. J., Ming, W., Gao, H., Yu, C., Xu, W. G., Brown, N. E., Dowless, M. S., Pulliam, N., Barda, D. A., Guo, D., Boulet, S. L., Huber, L., Capen, A., Jones, B., Bogner, S., Castanares, M. A., Stephens, J. R., Johnson, M. A., Curtis, C. L., Strelow, J. M., Xiao, J., Ballard, J., Bocchinfuso, W. P., Chalmers, M. J., Wang, J., Hendle, J., Saflor, M. D., Lagutan, D. M., Gheyi, T., Sarkar, A., Kearins, M., Tung, F., Ho, J., Rodgers, L., Benach, J., Frommelt, A. J., Zhou, L., Ackermann, B. L., McCann, D., Klippel, A., Buchanan, S. G., Henry, J. R., & Gong, X.
Affiliations
Eli Lilly (United States) (US)
Corresponding author
Gong, Xueqian
Venue
Nature Communications
Published
2026-05-04
Volume
17
Issue
1
ISSN
2041-1723 (ISSN-L)
OpenAlex
W7160046545
Cited by
1
References
0
Citations by year
2026: 1
FWCI
2.05
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
Eli Lilly and Company
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
Keywords
KRAS G12C inhibitors, covalent inhibitors, drug resistance, second-site mutations, immune checkpoint inhibitors, combination immunotherapy, ERK1/2 phosphorylation, tumor growth inhibition
MeSH terms
Immune Checkpoint Inhibitors, Animals, Antineoplastic Agents, Humans, Mutation, Proto-Oncogene Proteins p21(ras), Xenograft Model Antitumor Assays, Cell Line, Tumor, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Characterization of KRASG12C inhibitor olomorasib single-agent and combination with activity in KRASG12C-mutant models. https://app.cochat.ai/papers/10.1038/s41467-026-72650-y
The paper
Peng, S., Zhang, Y., Lin, X., Si, C., Van Horn, R. D., Dempsey, J. A., Goetz, E., Evans, R. J., Farber, A., Vandekopple, M. J., Ming, W., Gao, H., Yu, C., Xu, W. G., Brown, N. E., Dowless, M. S., Pulliam, N., Barda, D. A., Guo, D., . . . Gong, X. (2026). Characterization of KRASG12C inhibitor olomorasib single-agent and combination with activity in KRASG12C-mutant models. Nature Communications. https://doi.org/10.1038/s41467-026-72650-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.